Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Predictors of response to intravenous Solu-Medrol in endocrine orbitopathy
2010-018289-21Phase 4Terminated
- Sponsor
- Institute of Endocrinology
- Start
- Jan 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of methylprednisolone sodium succinate in Graves Orbitopathy (GO), sponsored by Institute of Endocrinology. Primary endpoint: Prediction of response to intravenous glucocorticoids. Started Jan 2010; status: terminated.
02
Drugs
methylprednisolone sodium succinate
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on 2010-018289-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018289-21.